VBIV vs. CKPT, MNOV, VHAQ, AEON, CELU, GNLX, RLYB, LTRN, LPTX, and RMTI
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include Checkpoint Therapeutics (CKPT), MediciNova (MNOV), Viveon Health Acquisition (VHAQ), AEON Biopharma (AEON), Celularity (CELU), Genelux (GNLX), Rallybio (RLYB), Lantern Pharma (LTRN), Leap Therapeutics (LPTX), and Rockwell Medical (RMTI). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.
Checkpoint Therapeutics has higher earnings, but lower revenue than VBI Vaccines.
In the previous week, Checkpoint Therapeutics had 4 more articles in the media than VBI Vaccines. MarketBeat recorded 5 mentions for Checkpoint Therapeutics and 1 mentions for VBI Vaccines. VBI Vaccines' average media sentiment score of 0.00 equaled Checkpoint Therapeutics'average media sentiment score.
Checkpoint Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.
VBI Vaccines has a net margin of -881.79% compared to VBI Vaccines' net margin of -50,336.89%. VBI Vaccines' return on equity of 0.00% beat Checkpoint Therapeutics' return on equity.
22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 10.4% of VBI Vaccines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Checkpoint Therapeutics currently has a consensus price target of $22.60, suggesting a potential upside of 1,095.77%. Given VBI Vaccines' higher probable upside, research analysts clearly believe Checkpoint Therapeutics is more favorable than VBI Vaccines.
VBI Vaccines received 329 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 74.29% of users gave VBI Vaccines an outperform vote while only 66.28% of users gave Checkpoint Therapeutics an outperform vote.
Summary
Checkpoint Therapeutics and VBI Vaccines tied by winning 7 of the 14 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
